327 related articles for article (PubMed ID: 12621733)
1. [In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin].
Shimizu M; Tabata M; Hara T; Araake M; Watabe H; Nishino T
Jpn J Antibiot; 2002 Dec; 55(6):791-9. PubMed ID: 12621733
[TBL] [Abstract][Full Text] [Related]
2. [In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone].
Araake M; Hara T; Watabe H; Nishino T
Jpn J Antibiot; 2002 Dec; 55(6):778-90. PubMed ID: 12621732
[TBL] [Abstract][Full Text] [Related]
3. [Inhibitory activity of NM394, the active form of prodrug prulifloxacin against type II topoisomerase from Pseudomonas aeruginosa].
Tani M; Maebashi K; Araake M; Watabe H
Jpn J Antibiot; 2002 Dec; 55(6):882-5. PubMed ID: 12621742
[TBL] [Abstract][Full Text] [Related]
4. In vivo antibacterial activity of a prodrug of NM394, a thiazetoquinoline carboxylic acid derivative.
Ozaki M; Tomii Y; Matsuda M; Segawa J; Kitano M; Kise M; Nishino T
Chemotherapy; 1998; 44(1):21-30. PubMed ID: 9444405
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice.
Tomii Y; Ozaki M; Matsuda M; Honmura T; Nishimura I; Yamaguchi R; Adachi T; Okawa Y; Nishino T
Arzneimittelforschung; 1996 Dec; 46(12):1169-73. PubMed ID: 9006794
[TBL] [Abstract][Full Text] [Related]
6. Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone.
Yoshida T; Mitsuhashi S
Antimicrob Agents Chemother; 1993 Apr; 37(4):793-800. PubMed ID: 8388199
[TBL] [Abstract][Full Text] [Related]
7. In vivo evaluation of NM441, a new thiazeto-quinoline derivative.
Ozaki M; Matsuda M; Tomii Y; Kimura K; Segawa J; Kitano M; Kise M; Shibata K; Otsuki M; Nishino T
Antimicrob Agents Chemother; 1991 Dec; 35(12):2496-9. PubMed ID: 1667252
[TBL] [Abstract][Full Text] [Related]
8. In vitro antibacterial activity of a new quinolone, NM394.
Ozaki M; Matsuda M; Tomii Y; Kimura K; Kazuno K; Kitano M; Kise M; Shibata K; Otsuki M; Nishino T
Antimicrob Agents Chemother; 1991 Dec; 35(12):2490-5. PubMed ID: 1667251
[TBL] [Abstract][Full Text] [Related]
9. [In vitro activity of prulifloxacin, levofloxacin and ciprofloxacin against urinary pathogens].
Noviello S; Ianniello F; Leone S; Esposito S
Infez Med; 2006 Mar; 14(1):24-8. PubMed ID: 17405239
[TBL] [Abstract][Full Text] [Related]
10. [In vitro antibacterial activity of prulifloxacin, a new oral quinolone, and comparative susceptibility rate at clinical breakpoint MIC].
Inoue M; Kuga A; Kaieda S; Hosaka M; Kitasato H; Sato Y; Okamoto R; Eda T; Hoshino K; Seto I
Jpn J Antibiot; 2000 Sep; 53(9):593-608. PubMed ID: 11214999
[TBL] [Abstract][Full Text] [Related]
11. [Antibacterial activity of gatifloxacin against various fresh clinical isolates in 2002].
Matsuzaki K; Watabe E; Yoshimori K; Shikano M; Sato Y; Hasegawa M; Kobayashi I
Jpn J Antibiot; 2002 Dec; 55(6):800-7. PubMed ID: 12621734
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance.
Gualco L; Schito AM; Schito GC; Marchese A
Int J Antimicrob Agents; 2007 Jun; 29(6):679-87. PubMed ID: 17363225
[TBL] [Abstract][Full Text] [Related]
13. Quinolone accumulation by Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli.
Piddock LJ; Jin YF; Ricci V; Asuquo AE
J Antimicrob Chemother; 1999 Jan; 43(1):61-70. PubMed ID: 10381102
[TBL] [Abstract][Full Text] [Related]
14. [In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates].
Matsuzaki K; Koyama H; Chiba A; Omika K; Harada S; Sato Y; Hasegawa M; Kobayashi I; Kaneko A; Sasaki J
Jpn J Antibiot; 1999 Sep; 52(9):571-84. PubMed ID: 10746192
[TBL] [Abstract][Full Text] [Related]
15. Uptake and intracellular activity of NM394, a new quinolone, in human polymorphonuclear leukocytes.
Ozaki M; Komori K; Matsuda M; Yamaguchi R; Honmura T; Tomii Y; Nishimura I; Nishino T
Antimicrob Agents Chemother; 1996 Mar; 40(3):739-42. PubMed ID: 8851603
[TBL] [Abstract][Full Text] [Related]
16. Effect of growth conditions on antimicrobial activity of DU-6859a and its bactericidal activity determined by the killing curve method.
Tanaka M; Hoshino K; Hohmura M; Ishida H; Kitamura A; Sato K; Hayakawa I; Nishino T
J Antimicrob Chemother; 1996 Jun; 37(6):1091-102. PubMed ID: 8836812
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone.
Hosaka M; Yasue T; Fukuda H; Tomizawa H; Aoyama H; Hirai K
Antimicrob Agents Chemother; 1992 Oct; 36(10):2108-17. PubMed ID: 1332587
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
Bauernfeind A
J Antimicrob Chemother; 1997 Nov; 40(5):639-51. PubMed ID: 9421311
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE
Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
[TBL] [Abstract][Full Text] [Related]
20. Postantibiotic effect of DU-6859a and levofloxacin as compared with ofloxacin.
Houston AK; Jones RN
Diagn Microbiol Infect Dis; 1994 Jan; 18(1):57-9. PubMed ID: 8026158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
